Friday May 15, 2015

5:30 pm  Registration

6:00 pm  Dinner

6:30 pm  Session 1: MCS In Special Populations
- Chemotherapy (Adriamycin
- HIV
- The Use of Mechanical Support in Adults with Congenital Heart Disease
- Peri Partum
- Restrictive and Obstructive Cardiomyopathies
- Acute Myocardial Infarction
- Who Should Not Receive a VAD: Pragmatism and Futility in Patient Selection

Frank Pagani, MD, PhD
Guilherme Oliveira, MD
Salpy Pamboukian, MD, MSPH
Christina VanderPluym, MD
Renzon Loyaga-Rendon, MD, PhD
John Stulak, MD
Deepak Acharya, MD
Joseph Rogers, MD
INTERMACS Ninth Annual Meeting
MCSDs in 2015: Evolution, Expansion, and Evaluation
May 15-16, 2015
Room: Salons 1 and 2

Saturday May 16, 2015

7:00 am  Registration

7:30 am  Session 2: INTERMACS Overview / Update
- Enrollment  James K. Kirklin, MD
- 4.0 Update / Relaunch / Waiver of Consent / WBDE  David C. Naftel, PhD

7:40 am  Session 3: Patterns of MCS Utilization  James Young, MD
- Impact of MCS Complications on Transplant Status  Todd Dardas, MD, MS
- Temporary Devices as a Bridge to More Permanent MCS  Eduardo Rame, MD, MPhil, MS
- RVAD Utilization  Michael Kiernan, MD, MS

8:30 am  Session 4: Pediatric Device Issues  David Rosenthal, MD
- First 100 Patients (or 200 Patients)  Elizabeth Blume, MD
- Impact of MCS Therapy on Pediatric Transplantation  Chris Almond, MD

9:00 am  Session 5: New Pump Updates  Robert Kormos, MD
- MVAD / Circulite Update  Katrin Leadley, MD
- HeartMate III Update  David Farrar, PhD
- SynCardia 50mL  Francisco Arabia, MD, MBA

9:45 am  Break

10:15 am  Session 6: Quality of Life  Kathy Grady, PhD, APN
- Quantifying the Impact of Adverse Events on Health-related Quality of Life Early after Implant  Kathy Grady, PhD, APN
- Patient Selection and Estimation of Prognosis after LVAD Implant: Use of Health Status Measures  Kelsey Flint, MD
- Predicting Patients at Risk for Poor Global  Suzanne Arnold, MD
Outcomes after DT MCS Therapy

11:00 am  Session 7: New Surgical Strategies
- Non-sternotomy Surgical Approaches for Implantation of Continuous Flow VADS
- Size Limitations for Current Continuous Flow Pumps: How young can we go?

11:30 am  Session 8: Hospital / Quality Assurance / Joint Commission
- Using QA Data to Guide a Successful VAD Program
- Joint Commission View on MCS QA
- Hospital Challenges in MCS Utilization

12:15 pm  Lunch & Awards Ceremony

1:15 pm  Session 9: Pump Thrombosis Update
- Anticoagulation: Review of Best Practices
- Continuous Flow Pump Thrombosis Update

1:45 pm  Session 10: Decision Making Challenges
- Presenting Choices to Patients
- The Roadmap for Medical Patients
- Medamacs: Who Gets to the End of Medical Therapy
- Are BTT / DT Designations Still Relevant to VAD Outcomes
- Panel Discussion: Projecting Outcomes for Ambulatory Patients without VAD
- INTERMACS Risk Model for MCS Outcomes in Ambulatory Profiles 4-6
- Questions

3:00 pm  Adjourn